Vitrolife AB  VITR ( SE0011205202 )

Company Fact Sheet

Company Profile
Vitrolife AB is a medical device company. It develops, produces, and markets products for creating, prolonging, and improving life. The company’s geographical segment includes EMEA, North and South America, Japan and Pacific and Asia. It derives a majority of revenue from the EMEA region. The company’s product categories include Oocyte retrieval Needles; Sperm processing; IVF media and oil; Micromanipulation pipettes; Labware; Benchtop incubators; Time-lapse systems; Preimplantation Genetic Testing (PGT); Cryopreservation; Laser and imaging systems and Lab QC systems.

Key Stats
Website http://www.vitrolife.com
Headquarter country Sweden
Employees 405
Market Cap (at close 21/08/2020 ) SEK24.81Bil
Morningstar Sector Healthcare
Morningstar Industry Medical Devices
Stock Style Small-Growth
Fiscal Year Ends December

Board of Directors and Management
Chairman of the Board Jon Sigurdsson
Chief Executive Officer Thomas Axelson
Chief Financial Officer Mikael Engblom

Source: Annual Report, Fiscal Year: 2019

Dividends(SEK)

<table>
<thead>
<tr>
<th>Ex Date</th>
<th>Payment</th>
<th>Type</th>
<th>Currency</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/05/2019</td>
<td>09/05/2019</td>
<td>Cash</td>
<td>SEK</td>
<td>0.85</td>
</tr>
<tr>
<td>27/04/2018</td>
<td>04/05/2018</td>
<td>Cash</td>
<td>SEK</td>
<td>0.74</td>
</tr>
<tr>
<td>28/04/2017</td>
<td>05/05/2017</td>
<td>Cash</td>
<td>SEK</td>
<td>0.52</td>
</tr>
<tr>
<td>29/04/2016</td>
<td>06/05/2016</td>
<td>Cash</td>
<td>SEK</td>
<td>0.48</td>
</tr>
<tr>
<td>06/05/2015</td>
<td>12/05/2015</td>
<td>Cash</td>
<td>SEK</td>
<td>0.30</td>
</tr>
</tbody>
</table>

Profitability and Valuation(SEK)

<table>
<thead>
<tr>
<th>Years</th>
<th>5 Yr Trend</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return on Assets %</td>
<td></td>
<td>19.7</td>
<td>18.9</td>
<td>20.13</td>
</tr>
<tr>
<td>Return on Equity %</td>
<td></td>
<td>23.5</td>
<td>22.8</td>
<td>23.3</td>
</tr>
<tr>
<td>Return on Invested Capital %</td>
<td></td>
<td>23.1</td>
<td>22.7</td>
<td>22.8</td>
</tr>
</tbody>
</table>

If data are missing or you find incorrect information in the Fact Sheet, please send an email to: support.nordics@morningstar.com

Please find the FAQ and Methodology at: www.nasdaqomxnordic.com/fact-sheet
### Profitability Analysis (SEK)

**Current** | 3 Yr Avg | 5 Yr Avg | 10 Yr Avg
---|---|---|---
Return on Equity % | 16.90 | 23.19 | 22.74 | 27.96
Return on Assets % | 14.16 | 19.85 | 18.80 | 20.68
Return on Invested Capital % | 16.20 | 22.98 | 22.02 | 25.08
Fixed Asset Turnover | 7.82 | 11.90 | 10.60 | 7.46
Inventory Turnover | 2.35 | 2.63 | 2.54 | 2.31

**Gross Margin %** | 61.08 | 64.89 | 65.47 | 66.41
Operating Margin % | 27.95 | 33.20 | 31.49 | 23.80
Net Margin % | 22.12 | 25.99 | 25.10 | 26.98

**Financial Position (SEK, Mil)**

| 2018 | 2019 |
---|---|
Cash and cash equivalents | 491 | 690 |
Inventory | 161 | 209 |
Accounts receivable | 181 | 233 |
Current Assets | 851 | 1,150 |
Net PP&E | 94 | 173 |
Intangibles | 728 | 778 |
Total Assets | 1,697 | 2,139 |
Accounts Payable | 32 | 29 |
Current Debt | 0 | 15 |
Current Liabilities | 152 | 202 |
Long Term Debt (Mil) | 0 | 61 |
Total Liabilities | | |
Total Equity (Mil) | 1,493 | 1,794 |

**Quarterly Results (SEK)**

| Revenue Mil | Q3 | Q4 | Q1 | Q2 |
---|---|---|---|---|
Most Recent | 378 | 409 | 334 | 209 |
Prior Year | 284 | 320 | 312 | 381 |

**Revenue Growth %**

| Most Recent | -0.72 | 8.33 | -18.47 | -37.35 |
| Prior Year | 0.28 | 12.71 | -2.56 | 22.06 |

**Earnings Per Share %**

| Most Recent | 0.98 | 0.89 | 0.74 | 0.11 |
| Prior Year | 0.89 | 0.77 | 0.79 | 0.87 |

### Valuation Analysis

**Current** | 3 Yr | 5 Yr | 10 Yr
---|---|---|---
Price/Earnings | 84.35 | 55.11 | 50.03 | 40.46 |
Forward Price/Earnings | - | - | - | - |
Price/Free Cash Flow | 74.80 | 65.20 | 58.56 | 46.30 |
Dividend Yield % | - | 0.45 | 0.50 | 0.79 |
Price/Book | 13.17 | 11.89 | 10.46 | 4.56 |
Price/Sales | 18.65 | 14.35 | 12.60 | 8.12 |

### Industry Peers by Market Cap SEK

| Mkt Cap (Mil) | P/E | ROE % |
---|---|---|
Vitrolife AB | 24,815 | 84.4 | 16.9 |
Sectra AB | 22,834 | 96.3 | 30.7 |
CellVision AB | 7,227 | 81.2 | 25.1 |
CELUNK AB | 6,017 | - | -9.0 |
Barclund Holding AB | 5,719 | 406.0 | 3.6 |
Xivio Perfusion AB | 5,387 | - | -1.1 |
Medistim ASA | 4,207 | 58.9 | 30.1 |